Search results
Earnings call: Aptose Biosciences targets AML treatment with tuspetinib By Investing.com
Investing.com· 12 hours agoAptose Biosciences (NASDAQ:APTO) has focused its efforts on developing tuspetinib as part of a novel...
Q1 2024 Bio Path Holdings Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 35 minutes agoTurning now to the progress we have made with our lead product candidate, prexigebersen. As you know, last year, we reported positive interim results from Stage 2 of our Phase 2 clinical trial ...
Study: Older Adults With Aggressive Blood Cancer A | Newswise
Newswise· 6 days agoStandard of care treatment for acute myeloid leukemia (AML) is safe and effective for adults over...
Ryvu Therapeutics First Quarter 2024 Financial Results and Corporate Update
CBS 47 Fresno· 23 hours agoAs of May 9, 2024, Ryvu's cash position was $59.0M, inclusive of the first tranche of €8M in venture debt from the EIB, obtained in March. This cash position, and other secured funding sources ...
Patients Over 80 Still Benefit From Treatment for AML Blood Cancer
Alaska Superstation· 2 days agoSeniors over 80 with acute myeloid leukemia can safely and effectively take the standard targeted...
Toddler, 2, dies months after his snoring was mistaken for a 'chesty cough'
The US Sun· 17 hours agoThe concerned mum took him to the GP four times in three months but when Mason started vomiting,...
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 3 hours agoEHA 2024 | Results from Five Studies of Ascentage Pharma's Key Drug Candidates Selected for Presentations at 2024 European Hematology Association Hybrid Congress PR Newswire SUZHOU, China and ROCKVILLE, Md., May 15, 2024 SUZHOU, China and ROCKVILLE
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 4 days agoSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q1 2024 Earnings Call Transcript May 8, 2024 Syndax...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 10 hours agoPRESS RELEASE AB SCIENCE PRESENTS ITS FINANCIAL INFORMATION AS OF DECEMBER 31, 2023 AND THE KEY EVENTS OF THE PERIOD Clinical development Continuation of the conditional marketing authorisation application procedures with
PhALLCON Soars to New Heights—Faster, Stronger, but Better?
Journal of the American Medical Association· 7 days agoIn this issue of JAMA, Jabbour and colleagues1 report results from the interim analysis of the PhALLCON randomized trial with ponatinib vs imatinib, combined with reduced-intensity chemotherapy ...
